These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 28088251)

  • 1. Lucerastat, an iminosugar with potential as substrate reduction therapy for glycolipid storage disorders: safety, tolerability, and pharmacokinetics in healthy subjects.
    Guérard N; Morand O; Dingemanse J
    Orphanet J Rare Dis; 2017 Jan; 12(1):9. PubMed ID: 28088251
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lucerastat, an Iminosugar for Substrate Reduction Therapy: Pharmacokinetics, Tolerability, and Safety in Subjects With Mild, Moderate, and Severe Renal Function Impairment.
    Guérard N; Zwingelstein C; Dingemanse J
    J Clin Pharmacol; 2017 Nov; 57(11):1425-1431. PubMed ID: 28618006
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of the organic cation transporter 2 inhibitor cimetidine on the single-dose pharmacokinetics of the glucosylceramide synthase inhibitor lucerastat in healthy subjects.
    Boof ML; Halabi A; Ufer M; Dingemanse J
    Eur J Clin Pharmacol; 2020 Mar; 76(3):431-437. PubMed ID: 31836927
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of the glucosylceramide synthase inhibitor lucerastat on cardiac repolarization: results from a thorough QT study in healthy subjects.
    Mueller MS; Sidharta PN; Voors-Pette C; Darpo B; Xue H; Dingemanse J
    Orphanet J Rare Dis; 2020 Oct; 15(1):303. PubMed ID: 33109218
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lucerastat, an Iminosugar for Substrate Reduction Therapy: Tolerability, Pharmacodynamics, and Pharmacokinetics in Patients With Fabry Disease on Enzyme Replacement.
    Guérard N; Oder D; Nordbeck P; Zwingelstein C; Morand O; Welford RWD; Dingemanse J; Wanner C
    Clin Pharmacol Ther; 2018 Apr; 103(4):703-711. PubMed ID: 28699267
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics, Safety Profile, and Tolerability of Tetramethylpyrazine Nitrone Tablets After Single and Multiple Ascending Doses in Healthy Chinese Volunteers.
    Zhu G; Wang L; Zhong S; Han S; Peng H; Tong M; He X
    Eur J Drug Metab Pharmacokinet; 2024 Mar; 49(2):207-217. PubMed ID: 38381348
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and Pharmacokinetics of HRS-2261, a P2X3 Receptor Antagonist, in Healthy Subjects: A Randomized, Double-Blind, Placebo-Controlled Phase 1 Study.
    Fan Y; Zhang X; Zhang Q; Zheng L; Zhou R; Sun C; Wang X; Song K; He Z; Wang H; Zhang Q; Hu W
    Clin Pharmacokinet; 2024 Mar; 63(3):293-302. PubMed ID: 38198010
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety, Tolerability, and Pharmacokinetic Profile of the Novel Translocator Protein 18 kDa Antagonist ONO-2952 in Healthy Volunteers.
    Suto F; Wood AT; Kobayashi M; Komaba J; Duffy K; Bruce M
    Clin Ther; 2015 Sep; 37(9):2071-84. PubMed ID: 26249232
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of Single and Multiple Ascending Doses of BI 1358894 in Healthy Male Volunteers on Safety, Tolerability and Pharmacokinetics: Two Phase I Partially Randomised Studies.
    Fuertig R; Goettel M; Herich L; Hoefler J; Wiebe ST; Sharma V
    CNS Drugs; 2023 Dec; 37(12):1081-1097. PubMed ID: 38019355
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety, tolerability and pharmacokinetics of trimebutine 3-thiocarbamoylbenzenesulfonate (GIC-1001) in a randomized phase I integrated design study: single and multiple ascending doses and effect of food in healthy volunteers.
    Paquette JM; Rufiange M; Iovu Niculita M; Massicotte J; Lefebvre M; Colin P; Telmat A; Ranger M
    Clin Ther; 2014 Nov; 36(11):1650-64. PubMed ID: 25224876
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety, Tolerability, Pharmacokinetics, and Immunogenicity of a Novel Recombination Human Nerve Growth Factor in Healthy Chinese Subjects.
    Shen Q; Zhang M; Jin Y; Di X; Liu R; Wang Z
    CNS Drugs; 2023 Mar; 37(3):231-242. PubMed ID: 36811740
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of Benfotiamine in Healthy Subjects.
    Sheng L; Cao W; Lin P; Chen W; Xu H; Zhong C; Yuan F; Chen H; Li H; Liu C; Yang M; Li X
    Drug Des Devel Ther; 2021; 15():1101-1110. PubMed ID: 33727798
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety, tolerability, and pharmacokinetics of the novel pan-phosphodiesterase inhibitor ZSP1601 in healthy subjects: a double-blinded, placebo-controlled first-in-human single-dose and multiple-dose escalation and food effect study.
    Zhu X; Wu M; Wang H; Li H; Lin J; Peng Y; Hu Y; Li C; Ding Y
    Expert Opin Investig Drugs; 2021 May; 30(5):579-589. PubMed ID: 33682556
    [No Abstract]   [Full Text] [Related]  

  • 14. Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Stapokibart in Healthy Volunteers and Adult Subjects with Atopic Dermatitis.
    Zhang L; Zhang W; Xu Y; Dong L; Sun Y; Jia Y; Li Z; Chen B; Hou J; Zhang J
    Adv Ther; 2024 Jul; 41(7):2953-2965. PubMed ID: 38833140
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An open-label study to determine the pharmacokinetics and safety of migalastat HCl in subjects with impaired renal function and healthy subjects with normal renal function.
    Johnson FK; Mudd PN; DiMino T; Vosk J; Sitaraman S; Boudes P; France N; Barlow C
    Clin Pharmacol Drug Dev; 2015 Jul; 4(4):256-61. PubMed ID: 27136905
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety, Tolerability and Pharmacokinetics of Single and Repeat Doses of Vixotrigine in Healthy Volunteers.
    Naik H; Steiner DJ; Versavel M; Palmer J; Fong R
    Clin Transl Sci; 2021 Jul; 14(4):1272-1279. PubMed ID: 33278330
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Phase 1, Randomised, Placebo-Controlled, Dose Escalation Study to Investigate the Safety, Tolerability and Pharmacokinetics of Cannabidiol in Fed Healthy Volunteers.
    Perkins D; Butler J; Ong K; Nguyen TH; Cox S; Francis B; Mcintosh M; Lilley B
    Eur J Drug Metab Pharmacokinet; 2020 Oct; 45(5):575-586. PubMed ID: 32409982
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SPH3127: A Phase I, Randomized, Double-Blind, Placebo-Controlled Trial.
    Jing S; Xu R; Yang K; Liu W; Zhang L; Ke Y; Xia G; Lin Y
    Clin Ther; 2021 Apr; 43(4):735.e1-735.e14. PubMed ID: 33653620
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety, tolerability, and pharmacokinetics of the novel RdRp inhibitor SHEN26 against SARS-CoV-2: a randomized, placebo-controlled, double-blind Phase I study in healthy subjects.
    Sun C; Liu H; Ouyang Z; Ding J; Zhang Q; Ma H; Xu D; Zhang Q; Zhou R; Yang M; Hu W
    Expert Opin Investig Drugs; 2024 May; 33(5):533-542. PubMed ID: 38662639
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety, tolerability, pharmacokinetics, and pharmacodynamics of PF-06650833, a selective interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitor, in single and multiple ascending dose randomized phase 1 studies in healthy subjects.
    Danto SI; Shojaee N; Singh RSP; Li C; Gilbert SA; Manukyan Z; Kilty I
    Arthritis Res Ther; 2019 Dec; 21(1):269. PubMed ID: 31805989
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.